511 related articles for article (PubMed ID: 16779740)
1. Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).
Ward JI; Cherry JD; Chang SJ; Partridge S; Keitel W; Edwards K; Lee M; Treanor J; Greenberg DP; Barenkamp S; Bernstein DI; Edelman R;
Clin Infect Dis; 2006 Jul; 43(2):151-7. PubMed ID: 16779740
[TBL] [Abstract][Full Text] [Related]
2. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study.
Le T; Cherry JD; Chang SJ; Knoll MD; Lee ML; Barenkamp S; Bernstein D; Edelman R; Edwards KM; Greenberg D; Keitel W; Treanor J; Ward JI;
J Infect Dis; 2004 Aug; 190(3):535-44. PubMed ID: 15243929
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of an acellular pertussis vaccine among adolescents and adults.
Ward JI; Cherry JD; Chang SJ; Partridge S; Lee H; Treanor J; Greenberg DP; Keitel W; Barenkamp S; Bernstein DI; Edelman R; Edwards K;
N Engl J Med; 2005 Oct; 353(15):1555-63. PubMed ID: 16221778
[TBL] [Abstract][Full Text] [Related]
4. Serologic response and antibody-titer decay in adults with pertussis.
Heininger U; Cherry JD; Stehr K
Clin Infect Dis; 2004 Feb; 38(4):591-4. PubMed ID: 14765356
[TBL] [Abstract][Full Text] [Related]
5. A trial of acellular pertussis vaccine in hospital workers during the Cincinnati pertussis epidemic of 1993.
Christie CD; Garrison KM; Kiely L; Gupta RK; Heubi J; Marchant CD
Clin Infect Dis; 2001 Oct; 33(7):997-1003. PubMed ID: 11528571
[TBL] [Abstract][Full Text] [Related]
6. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
McIntyre PB; Turnbull FM; Egan AM; Burgess MA; Wolter JM; Schuerman LM
Vaccine; 2004 Dec; 23(3):380-5. PubMed ID: 15530684
[TBL] [Abstract][Full Text] [Related]
7. Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection.
Barkoff AM; Gröndahl-Yli-Hannuksela K; Vuononvirta J; Mertsola J; Kallonen T; He Q
Vaccine; 2012 Nov; 30(48):6897-902. PubMed ID: 22981763
[TBL] [Abstract][Full Text] [Related]
8. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine.
Edelman KJ; He Q; Makinen JP; Haanpera MS; Tran Minh NN; Schuerman L; Wolter J; Mertsola JA
Clin Infect Dis; 2004 Jul; 39(2):179-85. PubMed ID: 15307026
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults.
Cherry JD; Chang SJ; Klein D; Lee M; Barenkamp S; Bernstein D; Edelman R; Decker MD; Greenberg DP; Keitel W; Treanor J; Ward JI
Clin Infect Dis; 2004 Dec; 39(11):1715-8. PubMed ID: 15578376
[TBL] [Abstract][Full Text] [Related]
10. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
[TBL] [Abstract][Full Text] [Related]
11. Immunity to pertussis 5 years after booster immunization during adolescence.
Edelman K; He Q; Mäkinen J; Sahlberg A; Haanperä M; Schuerman L; Wolter J; Mertsola J
Clin Infect Dis; 2007 May; 44(10):1271-7. PubMed ID: 17443462
[TBL] [Abstract][Full Text] [Related]
12. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria.
Rendi-Wagner P; Paulke-Korinek M; Stanek G; Khanakah G; Kollaritsch H
Pediatr Infect Dis J; 2007 Sep; 26(9):806-10. PubMed ID: 17721375
[TBL] [Abstract][Full Text] [Related]
13. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L
APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126
[TBL] [Abstract][Full Text] [Related]
14. Cellular immunity in adolescents and adults following acellular pertussis vaccine administration.
Meyer CU; Zepp F; Decker M; Lee M; Chang SJ; Ward J; Yoder S; Bogaert H; Edwards KM
Clin Vaccine Immunol; 2007 Mar; 14(3):288-92. PubMed ID: 17267589
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
Gustafsson L; Hessel L; Storsaeter J; Olin P
Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.
Knuf M; Zepp F; Meyer C; Grzegowski E; Wolter J; Riffelmann M; Wirsing von König CH
Vaccine; 2006 Mar; 24(12):2043-8. PubMed ID: 16356597
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
Chan SH; Tan PT; Han HH; Bock HL
Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
[TBL] [Abstract][Full Text] [Related]
18. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis.
Purdy KW; Hay JW; Botteman MF; Ward JI
Clin Infect Dis; 2004 Jul; 39(1):20-8. PubMed ID: 15206048
[TBL] [Abstract][Full Text] [Related]
20. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.
Thierry-Carstensen B; Dalby T; Stevner MA; Robbins JB; Schneerson R; Trollfors B
Vaccine; 2013 Oct; 31(45):5178-91. PubMed ID: 23994021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
